Immune imbalance and autoimmune mechanisms in plasma cell mastitis: current perspectives

Bo Xue, Yuang Jiang, Lei Yan, Xin Liu, Jie Li, Y. Li, Binyue Zhang, Yú Chen, Hongyan JiaFrontiers in Cell and Developmental Biology 2026 · DOI

Abstract

Plasma cell mastitis (PCM), also termed ductal dilatation or periductal mastitis (PDM), is a benign, non-bacterial inflammatory breast disorder predominantly affecting non-lactating women. Its incidence continues to rise, yet diagnosis and therapeutic approaches remain under development. Consequently, elucidating the pathogenesis is essential for identifying the disease's root cause and facilitating breakthroughs. PCM is increasingly regarded as an autoimmune disorder, highlighting the crucial role of immune factors in its development; however, the precise immune mechanisms involved remain incompletely understood. Against these backgrounds, this review aims to: (1) discuss the contributions of various innate and adaptive immune cells within the PCM-associated immune microenvironment; (2) describe the relationship between imbalances in key immune cells (including M1/M2 macrophages, Th1/Th2 lymphocytes, Th17/Treg cells) and the progression of PCM; (3) explore potential future research areas, the underlying immunopathogenesis of PCM, and prospective therapeutic targets, the activation of the complement system, regulation of immune homeostasis, the role of immune cell circadian rhythms, and modulation of key immune pathways.

Introduction: The Clinical Challenge of PCM

Plasma Cell Mastitis (PCM) is a chronic, non-bacterial inflammatory breast disease that primarily affects non-lactating women. Despite its rising incidence, it remains a significant clinical challenge, frequently misdiagnosed as breast cancer or granulomatous mastitis (GLM). Current standard treatments, including surgical excision and corticosteroid therapy, are often unsatisfactory due to high recurrence rates and debilitating side effects.

Recent research has shifted the paradigm of PCM from a localized inflammatory response to a complex autoimmune disorder. This perspective suggests that PCM is driven by "sterile inflammation," where the body’s immune system mistakenly targets mammary tissue in response to non-infectious damage signals. Understanding this unified pathogenic framework is critical for developing targeted, lower-risk therapeutic strategies.

The "Sterile Inflammation" Hypothesis

The initiation of PCM is likely triggered by Damage-Associated Molecular Patterns (DAMPs). These signals are released following mammary duct injury, which can be caused by physical trauma, nipple inversion, or hormonal imbalances such as high prolactin levels. These DAMPs mimic the presence of infection, activating Toll-like receptors (TLRs) on resident immune cells. This activation initiates a self-perpetuating inflammatory cascade in the absence of any bacterial pathogen, leading to the characteristic ductal dilatation and tissue remodeling seen in patients.

Innate Immune Dysregulation

A central feature of PCM is the profound imbalance within the innate immune system, particularly regarding macrophage polarization. In a healthy state, a balance exists between pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages. In PCM, this equilibrium shifts heavily toward the M1 phenotype.

Figure 1: Mechanism of action of innate immune cells in PCM, highlighting the transition from macrophage activation to epithelial cell destruction.

M1 macrophages secrete high levels of pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α, which aggravate the inflammatory response and lead to the destruction of mammary ductal epithelial cells. While M2 macrophages and regulatory mechanisms attempt to provide an "anti-inflammatory effect" via IL-10 and TGF-β, these "braking" signals are insufficient to halt the progression of the disease. Furthermore, neutrophils contribute to tissue damage through degranulation and the formation of neutrophil extracellular traps (NETs), while the complement system facilitates the formation of the Membrane Attack Complex (MAC), directly injuring the basement membrane.

Adaptive Immune Imbalance and Plasma Cell Infiltration

The adaptive immune system also exhibits significant dysregulation, characterized by a "tug-of-war" between Th17 and Treg cells. Th17 cells, which secrete the potent inflammatory mediator IL-17, dominate the PCM microenvironment, while the suppressive function of Treg cells is diminished.

Unique to this condition is the dense infiltration of plasma cells. Unlike their protective role in systemic immunity, these plasma cells may act as active pathogens in the context of PCM. They are thought to produce autoantibodies that exacerbate local tissue damage. Notably, these cells often express high levels of the anti-apoptotic protein Bcl-2, which may explain the persistence of the inflammation and its resistance to conventional treatments. Additionally, mammary epithelial cells may release exosomes carrying inflammatory cargo (such as NLRP3 vesicles), spreading autoimmune signals to neighboring cells and recruiting further immune infiltration.

Key Signaling Pathways and Therapeutic Targets

Synthesis of clinical and experimental data identifies the IL-6/JAK2/STAT3 axis as a primary driver of the "inflammatory storm" in PCM. In murine models, inhibiting this pathway using agents like AG-490 has shown success in reducing tissue damage.

Other high-confidence biomarkers include elevated levels of IFN-γ and TNF-α. The activation of the complement system also plays a pivotal role in ductal dilatation. Modulating these specific pathways, rather than employing broad-spectrum immunosuppression, represents a promising frontier for targeted PCM therapy.

Limitations and Future Directions

Despite progress, several gaps remain. There is a lack of PCM-specific diagnostic markers, as many identified cytokines (like IL-6) are common to various inflammatory states. Furthermore, the "IL-4 paradox"—where IL-4 promotes healing M2 macrophages but also drives the differentiation of the very plasma cells that define the disease—requires further investigation.

Future research may also explore "chronotherapy." The biological clock of immune cells likely influences PCM progression, and timing treatments to match these circadian rhythms could optimize efficacy. Developing high-fidelity animal models that accurately replicate the chronic, non-bacterial nature of human PCM remains a priority for validating these emerging theories.

Summary updated

Abstract

Plasma cell mastitis (PCM), also termed ductal dilatation or periductal mastitis (PDM), is a benign, non-bacterial inflammatory breast disorder predominantly affecting non-lactating women. Its incidence continues to rise, yet diagnosis and therapeutic approaches remain under development. Consequently, elucidating the pathogenesis is essential for identifying the disease's root cause and facilitating breakthroughs. PCM is increasingly regarded as an autoimmune disorder, highlighting the crucial role of immune factors in its development; however, the precise immune mechanisms involved remain incompletely understood. Against these backgrounds, this review aims to: (1) discuss the contributions of various innate and adaptive immune cells within the PCM-associated immune microenvironment; (2) describe the relationship between imbalances in key immune cells (including M1/M2 macrophages, Th1/Th2 lymphocytes, Th17/Treg cells) and the progression of PCM; (3) explore potential future research areas, the underlying immunopathogenesis of PCM, and prospective therapeutic targets, the activation of the complement system, regulation of immune homeostasis, the role of immune cell circadian rhythms, and modulation of key immune pathways.
BibTeX
@inproceedings{xue2026immune,
  author = {Bo Xue and Yuang Jiang and Lei Yan and Xin Liu and Jie Li and Y. Li and Binyue Zhang and Yú Chen and Hongyan Jia},
  title = {{Immune imbalance and autoimmune mechanisms in plasma cell mastitis: current perspectives}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  doi = {10.3389/fcell.2025.1727675},
}
Figure